Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Illinois Tool Works Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Illinois Tool Works Inc. trades at $269.23 (market cap $77.34B). The key difference: Illinois Tool Works Inc. is the larger of the two by market cap, and Illinois Tool Works Inc. pays a 2.4% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ITW | |
|---|---|---|
Market Cap | $39.89B | $77.34B |
Sector | Health | Industrials |
52-Week High | $491.22 | $299.60 |
52-Week Low | $278.09 | $241.07 |
Enterprise Value | $38.15B | $85.66B |
Dividend Yield | — | 2.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ITW trades at $268.81, up 1.25% with a bullish technical signal and strong profitability metrics including 19.32% net margin and 96.88% ROE. Recent earnings beats and a $1.61 dividend payment reflect operational strength, though cash flow trends show slight volatility. The stock is near resistance at $268 with analyst consensus target of $284.50.
Outlook remains positive with consistent earnings outperformance and margin expansion from enterprise initiatives. Risks include construction sector weakness and currency exposure. Wall Street shows mixed sentiment with 21% buy ratings, suggesting cautious optimism amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
